Drug Profile
BMS 986020
Alternative Names: AM-152; BMS-986020; BMS-986202Latest Information Update: 16 Mar 2021
Price :
$50
*
At a glance
- Originator Amira Pharmaceuticals
- Developer Bristol-Myers Squibb; Duke University
- Class Antifibrotics; Azabicyclo compounds; Carboxylic acids; Small molecules; Tetrazoles
- Mechanism of Action Lysophosphatidic acid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Idiopathic pulmonary fibrosis; Psoriasis
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for phase-I development in Psoriasis in Australia (PO, Capsule)
- 28 Jun 2019 No recent reports of development identified for phase-I development in Psoriasis in Australia (PO, Liquid)
- 17 May 2019 Discontinued - Phase-I for Psoriasis in Australia (PO) before May 2019, Australia (PO) before May 2019